South & Central America Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The South & Central America antibiotics and antimycotics market is projected to grow significantly, reaching approximately US$ 4,220.27 million by 2031, up from US$ 2,968.59 million in 2023, with an estimated compound annual growth rate (CAGR) of 4.5% during the forecast period.

Executive Summary and Market Analysis

The market is divided into key regions: Brazil, Argentina, and the Rest of South & Central America. This region plays a crucial role in the global antibiotics and antimycotics market and is anticipated to experience robust growth due to several factors. The rise in bacterial and fungal infections, strategic initiatives by market players-including product launches, approvals, and partnerships-and supportive government policies are driving this growth.

Market Segmentation

The South & Central America antibiotics and antimycotics market can be analyzed through various segments, including drug class, indication, route of administration, and distribution channel:

1. Drug Class: The market is categorized into penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin held the largest market share.

2. Indication: The market is segmented based on indications such as skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections accounted for the largest share in 2023.

3. Route of Administration: This market is divided into oral, topical, and other routes, with oral administration being the most prevalent in 2023.

4. Distribution Channel: The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2023.

Market Outlook

The pharmaceutical sector is increasingly integrating advanced technologies like deep learning, artificial intelligence (AI), and machine learning into the development of new antibiotics. Researchers are focused on creating tools and platforms to identify new active compounds. The use of innovative technologies is expected to transform the antibiotic and antimycotic development and approval processes.

One of the significant challenges in antibiotic development is targeting Gram-negative bacteria, which have restrictive cell membranes that limit antibiotic penetration. To address this, researchers have developed the Computational Antibiotic Screening Platform (CLASP), which aids in identifying potential drug molecules by analyzing porins. This platform enhances the efficiency of drug discovery by providing rapid thermodynamic and kinetic data for potential candidates.

There is also a growing trend towards precision medicine, which tailors antibiotic treatments based on individual genetic profiles and common resistance patterns. This approach aims to enhance drug efficacy while minimizing side effects and resistance development. Additionally, phage therapy is emerging as a novel treatment strategy, combining traditional antibiotics with bacteriophages to combat antibiotic-resistant pathogens. Recent advancements in gene-editing technologies, such as CRISPR, further bolster the potential of phage therapy, indicating a promising future for antibiotic and antimycotic treatments.

Country Insights

The South & Central America antibiotics and antimycotics market is primarily driven by Brazil, which held the largest market share in 2023. The growth in Brazil is attributed to the rising incidence of bacterial and fungal infections, along with increased awareness of antimicrobial resistance. The prevalence of hospital-acquired infections and diseases like pneumonia and tuberculosis, coupled with a high incidence of fungal infections among immunocompromised patients, is driving demand for antibiotics. Reports indicate that hospital infection rates in Brazil range from 5% to 14% of all hospitalizations, posing significant public health challenges.

Commonly prescribed antibiotics in Brazil include azithromycin, cefalexin, and amoxicillin, which are used to treat various bacterial infections. Regulatory bodies like ANVISA (National Health Surveillance Agency) oversee the market, ensuring the safety and efficacy of antibiotics and antimycotics while promoting responsible usage through public health initiatives. Furthermore, strategic initiatives by market players, such as product launches and partnerships, are expected to enhance market growth. For instance, in March 2024, Biocomposites received approval for STIMULAN, a calcium matrix antibiotic carrier for wound healing and bacterial infection treatment in Brazil.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Product Code: BMIRE00032108

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. South & Central America Antibiotics and Antimycotics Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Infectious Diseases
- 4.1.2 Growing Awareness About Fungal Infections
4.2 Market Restraints
- 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
4.3 Market Opportunities
- 4.3.1 Ongoing Funding and Research & Development Initiatives
4.4 Future Trends
- 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
4.5 Impact of Drivers and Restraints:

5. Antibiotics and Antimycotics Market - South & Central America Analysis

5.1 South & Central America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
5.2 South & Central America Antibiotics and Antimycotics Market Forecast Analysis

6. South & Central America Antibiotics and Antimycotics Market Analysis - by Drug Class

6.1 Penicillin
- 6.1.1 Overview
- 6.1.2 Penicillin: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Cephalosporines
- 6.2.1 Overview
- 6.2.2 Cephalosporines: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.3 Carbapenems
- 6.3.1 Overview
- 6.3.2 Carbapenems: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.4 Macrolides
- 6.4.1 Overview
- 6.4.2 Macrolides: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.5 Aminoglycosides
- 6.5.1 Overview
- 6.5.2 Aminoglycosides: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.6 Quinolones
- 6.6.1 Overview
- 6.6.2 Quinolones: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.7 Sulfonamides
- 6.7.1 Overview
- 6.7.2 Sulfonamides: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.8 Tetracyclines
- 6.8.1 Overview
- 6.8.2 Tetracyclines: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.9 Azoles
- 6.9.1 Overview
- 6.9.2 Azoles: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.10 Others
- 6.10.1 Overview
- 6.10.2 Others: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. South & Central America Antibiotics and Antimycotics Market Analysis - by Indication

7.1 Skin Infections
- 7.1.1 Overview
- 7.1.2 Skin Infections: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Respiratory Infections
- 7.2.1 Overview
- 7.2.2 Respiratory Infections: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Urinary Tract Infections (UTI)
- 7.3.1 Overview
- 7.3.2 Urinary Tract Infections (UTI): South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Septicemia
- 7.4.1 Overview
- 7.4.2 Septicemia: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Ear Infections
- 7.5.1 Overview
- 7.5.2 Ear Infections: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Gastrointestinal Infections
- 7.6.1 Overview
- 7.6.2 Gastrointestinal Infections: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. South & Central America Antibiotics and Antimycotics Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Topical
- 8.2.1 Overview
- 8.2.2 Topical: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. South & Central America Antibiotics and Antimycotics Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. South & Central America Antibiotics and Antimycotics Market - Country Analysis

10.1 South & Central America
- 10.1.1 South and Central America Antibiotics and Antimycotics Market Overview
- 10.1.2 South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.1 South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 10.1.2.2 Brazil: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.2.1 Brazil: South & Central America Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.2.2 Brazil: South & Central America Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.2.3 Brazil: South & Central America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.2.4 Brazil: South & Central America Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.3 Argentina: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.3.1 Argentina: South & Central America Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.3.2 Argentina: South & Central America Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.3.3 Argentina: South & Central America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.3.4 Argentina: South & Central America Antibiotics and Antimycotics Market Share - by Distribution Channel
  - 10.1.2.4 Rest of South & Central America: South & Central America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.2.4.1 Rest of South & Central America: South & Central America Antibiotics and Antimycotics Market Share - by Drug Class
    - 10.1.2.4.2 Rest of South & Central America: South & Central America Antibiotics and Antimycotics Market Share - by Indication
    - 10.1.2.4.3 Rest of South & Central America: South & Central America Antibiotics and Antimycotics Market Share - by Route Of Administration
    - 10.1.2.4.4 Rest of South & Central America: South & Central America Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Antibiotics and Antimycotics Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Pfizer Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Novartis AG
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sanofi SA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Merck & Co Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 GSK Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Johnson & Johnson
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Cipla Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Bayer AG
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 AbbVie Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Astellas Pharma Inc
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms